Thermo Fisher Scientific's $13.6 Billion Acquisition of Life Technologies Boosts Flagging M&A Numbers May 01, 2013 | Press Release
Burrill Securities Launches Institutional Breakthrough Series April 29, 2013 | Press Release
Big Biotech Outpaces Big Pharma, Burrill & Company says April 16, 2013 | Press ReleaseSee all News
Burrill Merchant Banking Newsletter Q3, 2006November 10, 2006
San Francisco, CA - November 10, 2006
Please click here to download our newsletter.
Burrill & Company is pleased to present our quarterly Merchant Banking Newsletter. In this issue we take a look at overall Partnering and M&A activity in the third quarter and then review personalized medicine and the increasing trend in regional deal-making. We hope you enjoy this issue.
To learn more about Burrill & Company Merchant Banking, and how we may be able to assist you, please visit our website at burrillandco.com/bio/strategic_partnering.
If you would like to discuss your strategic transaction needs and brainstorm with us about your company's future direction, either in person or via conference call, please contact one of our team members:
Our 20th annual report on the State of the Biotech Industry, Biotech 2006—Life Sciences: A Changing Prescription, is now available. To order a copy, please visit www.burrillandco.com/burrill/purchase_book
Burrill & Company
About Burrill Merchant Banking
Burrill Merchant Banking assists life science companies to identify, negotiate and close strategic transactions. Service lines include:
Merger & Acquisitions across life sciences
Strategic Partnering from early-stage research, to product development and commercialization
Spin-Outs and Divestitures to create a new company or build value in an established entity
Financing Advisory and Private Placement
Advisory Services defining the role of transactions in achieving strategic objectives
About Burrill & Company
Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with principal activities in Venture Capital, Merchant Banking and Media. It has over $725 million in venture capital funds under management and has completed numerous merchant banking transactions. The company¹s 50 person scientific and business team, supported by its nearly 40-person Advisory Boards, the strategic and financial network of its limited partners, and the close relationships developed with numerous life science companies and management, provide Burrill with unparalleled access and insight.
The company’s Media Group publishes an annual book on the "State of the Industry" the 20th Edition is Biotech 2006-Life Sciences: A Changing Prescription. Burrill also publishes a range of biotechnology/life science newsletters and reports and is also the sponsor and facilitator of over a dozen leading industry conferences. Full details may be found at: http://www.burrillandco.com
For more information please contact James Watson, Managing Director, Head of Merchant Banking at firstname.lastname@example.org.